Skip to main content
. 2021 Jun 2;12:689132. doi: 10.3389/fimmu.2021.689132

Figure 1.

Figure 1

Monoclonal antibodies and small molecules targeting VEGF/VEGFR signaling in tumor angiogenesis. Monoclonal antibodies and small molecule TKIs targeting the VEGFA/VEGFR-2/PLCγ/Raf/PI3K signaling pathway could inhibit tumor angiogenesis and improve the efficiency of anticancer treatments. VEGF, Vascular Endothelial Growth Factor; VEGFR, Vascular Endothelial Growth Factor Receptor; TKI, Tyrosine Kinase Inhibitor; PI3K, Phosphoitide 3-Kinase; AKT, serine/threonine-specific protein kinase; mTOR, mammalian target of rapamycin; PLCγ, Phospholipase C γ; PI3P, Phosphatidylinositol 3-Phosphate; IP3, Inositol Triphosphate; DAG, Diacyl Glycerol; pKC, Protein Kinase C; MEK, Mitogen-activated protein kinase; MAPK, Mitogen Activated Protein Kinase.